Research Article
Diagnostic Performance of 18F-FDG PET(CT) in Bone-Bone Marrow Involvement in Pediatric Neuroblastoma: A Systemic Review and Meta-Analysis
Table 1
Characteristic of involved studies.
| | Sources | Country | Study design | No. | Age | F/M | Scan model | Injection dose | Interval time | Imaging analysis | Analysis type | Stage (INSS) | Reference standard |
| | Choi et al. [10] | South Korea | R | 30 | 2.7 median | 18/12 | PET | 5.18 MBq/kg | 60 min | SUVmax | PB | I–IV | BMB/MRI | | Fawzy et al. [11] | Egypt | P | 30 | 3.77 mean | 16/14 | PET/CT | NA | NA | SUVmax | PB | III-IV | BMB | | Gil et al. [12] | South Korea | R | 8 | 3.6 median | 5/3 | PET | 400 MBq | 60 min | Visual | LB | III-IV | BMB | | Ishiguchi et al. [13] | Japan | R | 13 | 2.9 ± 2.0 mean | 6/7 | PET/CT | 3.7 MBq/kg | NA | Visual | LB | IV | BMB | | Tezol et al. [14] | Turkey | R | 11 | 2.3 ± 1.6 mean | NA | PET/CT | NR | 60 min | Visual | PB | NA | BMB | | Yağcı-Küpeli et al. [15] | Turkey | R | 15 | 4 median | 7/8 | PET/CT | 185 MBq | 60 min | Visual | PB | NA | BMB | | Zapata et al. [16] | USA | R | 20 | 3.8 mean | 12/8 | PET/CT | NA | NA | Visual | PB | NA | BMB |
|
|
Note: NA—not available, R—retrospective, P—prospective, No.—number of included patients, —the max injection dose, SUVmax—maximum standard uptake value, LB—lesion-based, PB—patient-based, INSS—International Neuroblastoma Staging System, BMB—bone marrow biopsy, MRI—magnetic resonance imaging. |
